AN UMBRELLA REVIEW ON TREATMENTS AND THERAPEUTIC OPTIONS FOR COVID-19 DOI Creative Commons
SeyedAhmad SeyedAlinaghi, Amir Masoud Afsahi, Ayoob Molla

et al.

Russian Journal of Infection and Immunity, Journal Year: 2023, Volume and Issue: 13(5), P. 885 - 898

Published: Oct. 20, 2023

Introduction. As the COVID-19 pandemic continues to pose a significant challenge global health, effective therapeutic options for preventing and treating disease have become increasingly important. We aimed provide an update on current treatments patients.Materials methods. The purpose of this umbrella review is explore patients. Keywords their combinations were searched across online databases in Embase, PubMed/MEDLINE, Web Science, Scopus spanning from July 1, 2020, through March 3, 2023. Publications selected data extraction two steps based study inclusion/exclusion criteria. adheres PRISMA checklist as well NIH bias risk quality assessment tool.Results. In review, 28 relevant articles final qualitative synthesis. majority included studies had reported efficacy Lopinavir/Ritonavir (n = 4), Ivermectin 3), Baricitinib 2), Tocilizumab Remdesivir ACEI/ARB Vitamin D Molnupiravir Traditional Chinese medicine (TCM) Convalescent plasma transfusion (CPT) 2) hydroxychloroquine COVID-19. It appeared that Baricitinib, Remdesivir, ACEI/ARB, TCM, CPT may beneficial effects reducing mortality, hospitalization duration, severity Other interventions, such Lopinavir/Ritonavir, Ivermectin, D, Hydroxychloroquine did not show clear benefits or inconclusive results.Conclusion. This provides comprehensive overview evidence effectiveness safety various pharmacological non-pharmacological interventions These results updated landscape treatments, highlighting potential avenues further research clinical practice. crucial continue monitoring emerging conducting rigorous guide development optimization strategies against

Language: Английский

Automated Paper Screening for Clinical Reviews Using Large Language Models: Data Analysis Study DOI Creative Commons
Eddie Guo, Mehul Gupta, Jiawen Deng

et al.

Journal of Medical Internet Research, Journal Year: 2023, Volume and Issue: 26, P. e48996 - e48996

Published: Sept. 28, 2023

The systematic review of clinical research papers is a labor-intensive and time-consuming process that often involves the screening thousands titles abstracts. accuracy efficiency this are critical for quality subsequent health care decisions. Traditional methods rely heavily on human reviewers, requiring significant investment time resources.

Language: Английский

Citations

51
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial DOI Creative Commons
Dhammika Leshan Wannigama, Cameron Hurst, Phatthranit Phattharapornjaroen

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 70, P. 102517 - 102517

Published: March 14, 2024

Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials studied combinations these agents. The aim this trial was to assess effectiveness affordable, widely available, repurposed used combination for which may be particularly relevant low-resource countries.

Language: Английский

Citations

9
Overview of the potential use of fluvoxamine for COVID-19 and long COVID DOI Creative Commons
Kenji Hashimoto

Discover Mental Health, Journal Year: 2023, Volume and Issue: 3(1)

Published: March 21, 2023

Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to public health since its emergence in late 2019. From safety point of view, drug repurposing received particular attention. Several clinical studies have demonstrated that the use fluvoxamine, selective serotonin reuptake inhibitor with potent sigma-1 receptor agonism, early-stage infection might be associated prevention deterioration individuals SARS-CoV-2 infection, although several reports shown low dose fluvoxamine may ineffective. There is increasing evidence can cross blood–brain barrier, resulting number psychiatric and neurologic symptoms COVID-19 survivors. Importantly, about half survivors experience variety long-term sequelae, including symptoms, known as long COVID. In this priority review, author presents an overview potential treatment

Language: Английский

Citations

20
Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders DOI
Wan‐Ju Cheng, Hong-Mo Shih, Kuan‐Pin Su

et al.

Brain Behavior and Immunity, Journal Year: 2023, Volume and Issue: 114, P. 255 - 261

Published: Aug. 29, 2023

Language: Английский

Citations

15
Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study DOI Creative Commons
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas

et al.

European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 71, P. 96 - 108

Published: April 4, 2023

The World Health Organization has proposed that a search be made for alternatives to vaccines the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought assess: impact previous SSRI antidepressants on severity COVID-19 (risk hospitalisation, admission an intensive care unit [ICU], mortality), its influence susceptibility SARS-CoV-2 progression severe COVID-19. We conducted population-based multiple case-control in region north-west Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) 95%CIs calculated using multilevel logistic regression. collected data total 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised PCR+ 56,785 controls (without PCR+). Citalopram displayed statistically significant decrease risk hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) (aOR=0.64; 0.43-0.96, 0.032). Paroxetine was associated mortality (aOR=0.34; 0.12 - 0.94, 0.039). No class effect observed SSRIs overall, nor any other found remaining SSRIs. results this large-scale, real-world indicate that, citalopram, could candidate drug repurposed as preventive aimed at reducing patients' progressing stages disease.

Language: Английский

Citations

13
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study DOI Creative Commons
Bruce Kirenga, Levicatus Mugenyi, Marina Sánchez‐Rico

et al.

Molecular Psychiatry, Journal Year: 2023, Volume and Issue: 28(12), P. 5411 - 5418

Published: March 3, 2023

Abstract Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook prospective interventional open-label cohort study to evaluate efficacy tolerability fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge complete symptom resolution. included 316 patients, whom 94 received addition standard care [median age, 60 years (IQR = 37.0); women, 52.2%]. Fluvoxamine use significantly associated reduced mortality [AHR 0.32; 95% CI 0.19–0.53; p < 0.001, NNT 4.46] increased resolution [AOR 2.56; 1.53–5.51; 4.44]. Sensitivity analyses yielded similar results. These effects did not differ by clinical characteristic, including vaccination status. Among 161 survivors, time 0.81, (0.54–1.23), 0.32]. There trend toward greater side (7.45% versus 3.15%; SMD 0.21; χ 2 3.46, 0.06), most which light or mild severity none serious. One hundred mg prescribed twice daily 10 days well tolerated resolution, without significant increase discharge, Large-scale randomized trials are urgently needed confirm these findings, especially low- middle-income countries, where access vaccines approved treatments is limited.

Language: Английский

Citations

12
Long COVID-19 and Peripheral Serotonin: A Commentary and Reconsideration DOI Creative Commons
George P. Anderson, Edwin H. Cook, Randy Blakely

et al.

Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 2169 - 2172

Published: April 1, 2024

Abstract: We believe there are serious problems with a recently published and highly publicized paper entitled "Serotonin reduction in post-acute sequelae of viral infection." The blood centrifugation procedure reportedly used by Wong et al would produce plasma that is substantially (over 95%) depleted platelets. Given this, their mean serotonin values 1.2 uM 2.4 for the control/contrast groups appear to be at least 30 60 times too high should disregarded. reported long COVID viremia patients also disregarded, as any comparisons groups. note means two not good agreement. In "Discussion" section, state results tend support use selective reuptake inhibitors (SSRIs) treatment COVID-19, they encourage further clinical trials SSRIs. While that, "Our animal models demonstrate levels can restored memory impairment reversed precursor supplementation or SSRI treatment", it noted no data presented showing an increase restoration circulating administration. fact, one expect marked decline platelet due SSRIs' effective inhibition transporter. hypothesize arise from little peripheral serotonin. However, given frequent presence hyperaggregation COVID, known augmenting effects on aggregation, plausible suggest reductions might associated lessening cardiovascular COVID-19. Keywords: serotonin, plasma, platelets, infection

Language: Английский

Citations

4
Exploring the causal effects of depression and antidepressants on COVID-19 DOI Creative Commons
Li Fu, Ancha Baranova, Hongbao Cao

et al.

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 359, P. 350 - 355

Published: May 25, 2024

Language: Английский

Citations

4
Mechanisms and Potential Benefits of Neuroprotective Agents in Neurological Health DOI Open Access
Burcu Pekdemir, António Raposo, Ariana Saraiva

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(24), P. 4368 - 4368

Published: Dec. 18, 2024

The brain contains many interconnected and complex cellular molecular mechanisms. Injury to the causes permanent dysfunctions in these So, it continues be an area where surgical intervention cannot performed except for removal of tumors repair some aneurysms. Some agents that can cross blood–brain barrier reach neurons show neuroprotective effects due their anti-apoptotic, anti-inflammatory antioxidant properties. In particular, act by reducing or modulating accumulation protein aggregates neurodegenerative diseases (Alzheimer’s disease, Parkinson’s Huntington’s Amyotrophic lateral sclerosis, prion disease) caused accumulation. Substrate increased oxidative stress stimulates brain’s immune cells, microglia, astrocytes, secrete proinflammatory cytokines. Long-term chronic neuroinflammatory response triggers apoptosis. Brain damage is observed with neuronal apoptosis functions are impaired. This situation negatively affects processes such as motor movements, memory, perception, learning. Neuroprotective prevent molecules play a role addition, they improve impaired supporting neuroplasticity neurogenesis. Due important roles central nervous system diseases, elucidate review provides overview mechanisms flavonoids, which constitute large part effects, well vitamins, neurotransmitters, hormones, amino acids, derivatives. It thought understanding will enable development new therapeutic different treatment strategies.

Language: Английский

Citations

4
Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis DOI Creative Commons
Jiawen Deng, Myron Moskalyk, Qi Zuo

et al.

Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 34(1)

Published: Dec. 26, 2023

Abstract This systematic review and meta‐analysis of randomised controlled trials (RCTs) aimed to evaluate the efficacy, safety, tolerability fluvoxamine for outpatient management COVID‐19. We conducted this in accordance with PRISMA 2020 guidelines. Literature searches were MEDLINE, EMBASE, International Pharmaceutical Abstracts, CINAHL, Web Science, CENTRAL up 14 September 2023. Outcomes included incidence hospitalisation, healthcare utilization (emergency room visits and/or hospitalisation), mortality, supplemental oxygen mechanical ventilation requirements, serious adverse events (SAEs) non‐adherence. Fluvoxamine 100 mg twice a day was associated reductions risk hospitalisation (risk ratio [RR] 0.75, 95% confidence interval [CI] 0.58–0.97; I 2 = 0%) (RR 0.68, CI 0.53–0.86; 0%). While no increased SAEs observed, higher treatment non‐adherence compared placebo 1.61, 1.22–2.14; 53%). In subgroup analyses, reduced outpatients BMI ≥30 kg/m , but not those lower BMIs. offers potential benefits reducing utilization, its efficacy may be most pronounced high‐risk patient populations. The observed rates highlight need better education counselling. Future investigations should reassess trial endpoints include outcomes relating post‐COVID sequelaes. Registration: prospectively registered on PROSPERO (CRD42023463829).

Language: Английский

Citations

9